AbbVie & Eisai’s Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan

 AbbVie & Eisai’s Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan

AbbVie & Eisai’s Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan

Shots:

  • The approval is based on Japanese P-III study results assessing Humira (adalimumab) in patients with moderate-to-severe HS, evaluating its efficacy and safety
  • The study resulted in meeting its 1EPs as HiSCR @12 wks. in 13/15 patients, ADRs in 6/15
  • Humira (adalimumab) is an anti-TNF-α mAb approved in Japan for rheumatoid arthritis (RA), plaque psoriasis, arthritic psoriasis, pustular psoriasis, ankylosing spondylitis

Click here to read full press release/ article | Ref: Eisai Co | Image: News Pharmaceutical

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post